Infographic: RA Perceptions
August 25, 2015 | Biologics, physicians, rheumatoid arthritis
HCPs predict the future of the biologics market
Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.
Download our RA Perceptions: Predicting the future of the European market infographic now »
RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.
Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.
Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.
Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.
The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Blog: Affordable Care Act
What does the future hold for the US pharma industry?
Webinar: How to conduct effective market research in emerging markets
Pharmaceutical market research is still evolving in many emerging markets and so finding the insights you require can be a challenge.
Webinar: Uncovering hidden insights into patient compliance
Pharma companies are increasingly looking for ways to provide “beyond the pill” services to support patients with the management of their disease. Adherence tools and programs encourage patients to stay compliant with their treatment…
Webinar: The patient journey: Time to look beyond the physician?
Treatment initiation is a key focus for many pharma companies as part of their strategy to increase script writing and drive greater revenues.
Webinar: Ensuring an actionable segmentation
One of the most consistent issues researchers face with segmentation is ensuring that it is actionable.
Webcast: Leveraging the ASEAN opportunities
Exploring the opportunities for pharma in the ASEAN region and factors to consider when conducting healthcare market research.
Webcast: Biosimilars: Friend or Foe to Healthcare?
Understanding the opportunities for biosimilars and the threats to innovator biologics
Webinar: Understanding the patient journey in China
The Chinese healthcare market is experiencing a period of great change. Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and considers…
Webinar: Capturing “in-the-moment” patient and physician insights
Utilising the benefits of mobile technology
Webinar: Observational Research
Presenting a window on the world of your customer